Open Label, Phase I ZD6474 Head and Neck Cancer Study

Sanofi48 enrolled

Overview

The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Head and Neck Cancer

Interventions

ZD6474 (vandetanib)DRUG

once daily oral dose

CisplatinDRUG

intravenous infusion

RadiationRADIATION

radiation of head and neck

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stage III-IV squamous cell carcinoma of the head and neck Exclusion Criteria: * No previous treatment for head and neck cancer, adequate cardiac function

Locations (4)

Research Site

Denver, Colorado, United States

Research Site

Chicago, Illinois, United States

Research Site

Dallas, Texas, United States

Research Site

Houston, Texas, United States

Outcomes

Primary Outcomes

To determine the maximum tolerated dose of vandetanib given in combination with radiation or radiation and chemotherapy in patients with late stage head and neck cancer

Time frame: assessed at each visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.